Advanced Pipeline

Product / Indication Pre Clinical Phase 1 Phase 2 Phase 3 Approved
BCDA-01 : CardiAMP Cell Therapy

Indication : Ischemic Heart Failure

Pivotal / Phase III has CMS reimbursement, actively enrolling at 18 U.S. sites

BCDA-02 : CardiAMP Cell Therapy

Indication : Chronic Myocardial Ischemia with Refractory Angina

Pivotal / Phase III has CMS reimbursement

BCDA-03 CardiALLO Cell Therapy

Indication : Ischemic Heart Failure

IND submission 2018 anticipated

Helix Partner 01: CellProthera

Indication: Acute Infarction

Funded by Partner

Helix Partner-02 : Univ of Milan

Indication : Heart Failure

Funded by partner

BioCardia is developing two comprehensive biotherapeutic candidates for cardiac regenerative medicine.

  • CardiAMP – autologous minimally processed bone marrow cells (a patient’s own cells)
  • CardiALLO allogenic culture expanded mesenchymal stem cells derived from bone marrow  (donor-derived)  

Both programs provide compelling and synergistic approaches to replicating the natural response of bone marrow cells to cardiac injury. CardiAMP harnesses the potential of autologous minimally processed bone marrow cells, using a pre-procedure screening test to identify patients most likely to benefit from the therapy.  CardiALLO utilizes younger, universal donor mesenchymal stem cells and may be appropriate for patients who are not optimal candidates for the CardiAMP therapy. 


News


Have questions?
CALL US NOW
: (800) 624-1179
Have questions?
EMAIL US NOW
: info@biocardia.com

biocardia takes a new and comprehensive
approach to heart failure

By introducing patient screening and highly-efficient delivery to stem cell therapy, the company seeks to increase the likelihood of treatment success, enabling more patients to return to the things they love.